What is the current Novavax market capitalization?
The current market capitalization of Novavax is 1.6 B USD.
Novavax Market capitalization 2024
Novavax Market capitalization
1.6 B USD
Ticker
NVAX
ISIN
US6700024010
WKN
A2PKMZ
In 2024, Novavax's market cap stood at 1.6 B USD, a 118.46% increase from the 731.58 M USD market cap in the previous year.
The Novavax Market capitalization history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) | NET INCOME (undefined USD) |
|---|---|---|---|
| 2029e | 1.26 | 50,99 | 98.83 |
| 2028e | 1.12 | 57,13 | 29.36 |
| 2027e | 1.06 | 60,65 | 12.17 |
| 2026e | 0.32 | 200,58 | -30.55 |
| 2025e | 0.39 | 166,12 | -141.8 |
| 2024e | 0.98 | 65,31 | 19.34 |
| 2023 | 0.98 | 65,10 | -545.06 |
| 2022 | 1.98 | 54,45 | -657.9 |
| 2021 | 1.15 | 55,87 | -1,743.8 |
| 2020 | 0.48 | 134,66 | -418.3 |
| 2019 | 0.02 | 3424,80 | -132.7 |
| 2018 | 0.03 | 1867,16 | -184.7 |
| 2017 | 0.03 | 2052,68 | -183.8 |
| 2016 | 0.02 | 4158,68 | -280 |
| 2015 | 0.04 | 1764,29 | -156.9 |
| 2014 | 0.03 | 51,14 | -82.9 |
| 2013 | 0.02 | 60,77 | -52 |
| 2012 | 0.02 | 33,48 | -28.5 |
| 2011 | 0.01 | 52,38 | -19.4 |
| 2010 | 0 | 100,00 | -35.7 |
| 2009 | 0 | 213479,00 | -40.3 |
| 2008 | 0 | 58221,55 | -34.5 |
| 2007 | 0 | 42695,80 | -34.8 |
| 2006 | 0 | 88,24 | -23.1 |
| 2005 | 0.01 | 92,45 | -11.2 |
| 2004 | 0.01 | 57,83 | -25.9 |
Novavax Aktienanalyse
What does Novavax do?
Novavax Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative vaccines and products for the treatment of infectious diseases. The company was founded in 1987 in Maryland, USA, and has since relocated its headquarters to Gaithersburg, Maryland. Novavax is a pioneer in vaccine technology. The company's business model is based on the development of vaccines for diseases such as malaria, Zika, RSV, and COVID-19. Novavax uses the latest technology and methods to ensure the highest efficacy and safety of its vaccines. By licensing its own technologies and licenses, the company has significantly increased its reach and effectiveness, establishing successful partnerships with institutions such as the Bill and Melinda Gates Foundation and the US Department of Defense. The different divisions of the company are focused on the development of vaccines and antiviral therapies. Novavax is involved in clinical development and has a portfolio of vaccine candidates targeting T-cells and antibodies. Currently, Novavax is conducting studies in the field of Respiratory Syncytial Virus (RSV) vaccination. The RSV program is Novavax's oldest program, launched in 1995, and the company has developed several vaccine candidates. A recent Phase III trial of an RSV vaccine candidate for the prevention of RSV infections in pregnant women did not meet its goals. However, it is a key position in vaccine development, allowing the company to focus on the development of vaccines against other infectious diseases. Novavax also has an ongoing research program focused on developing a COVID-19 vaccine candidate based on a protein called Nanoparticle Spike Protein (NVX-CoV2373) expressed in insect cells. A major advantage of this program is that it allows for faster manufacture of millions of doses with high throughput and has consistently shown positive results in clinical studies. The company has also developed a revolutionary technology called Matrix-M, which is used in its vaccines to enhance the immune response and activity against the vaccine. It is an adjuvant technology that stimulates the body to respond to a vaccine and achieve higher immunity against the pathogen. Novavax has a number of vaccine candidates in clinical development, including vaccines against malaria, influenza, and human papillomavirus (HPV), as well as an antiviral therapy for the treatment of RSV. These programs are still in the early stages of development, but the company is confident that it will be successful in the future. Overall, Novavax is a company specializing in the development of innovative vaccines and antiviral therapies for the treatment of infectious diseases. With a focus on safety, efficacy, and innovation, the company has achieved a leading position in vaccine technology and has become a key player in the global health landscape. Answer: Novavax is a biopharmaceutical company that specializes in developing and marketing innovative vaccines and products for treating infectious diseases. It was founded in 1987 in Maryland, USA, and focuses on developing vaccines against diseases like malaria, Zika, RSV, and COVID-19. The company uses advanced technology and methods to ensure the effectiveness and safety of its vaccines. It has partnerships with institutions like the Bill and Melinda Gates Foundation and the US Department of Defense. Novavax is also involved in clinical development and has a portfolio of vaccine candidates targeting T-cells and antibodies. Its oldest program is focused on developing an RSV vaccine, and it also has a program focused on developing a COVID-19 vaccine. Novavax has developed a technology called Matrix-M, which enhances the immune response to vaccines. It also has vaccine candidates in development for malaria, influenza, and HPV, as well as an antiviral therapy for RSV. Overall, Novavax is a leading company in vaccine technology and aims to develop effective and innovative vaccines and antiviral therapies for infectious diseases. Novavax ist eines der beliebtesten Unternehmen auf Eulerpool.com.Market capitalization Details
Exploring Novavax's Market Capitalization
Novavax's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.
Year-to-Year Comparison
A yearly comparison of Novavax's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.
Impact on Investments
Novavax's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.
Interpreting Market Capitalization Fluctuations
Variations in Novavax’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.
Frequently Asked Questions about Novavax Stock
What is market capitalization?
The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Novavax.
How has the market capitalization of Novavax developed in recent years?
The market capitalization of Novavax has increased/decreased by 118.46% compared to the previous year.
What does market capitalization mean for investors?
The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.
Why is market capitalization an important indicator for investors?
The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.
Why does the market capitalization fluctuate?
The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.
What role does market capitalization play in the valuation of Novavax?
In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.
Does the market capitalization influence the performance of Novavax?
There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
Does the market capitalization of Novavax have an influence on indices?
Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).
How much dividend does Novavax pay?
Over the past 12 months, Novavax paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Novavax is expected to pay a dividend of 0 USD.
What is the dividend yield of Novavax?
The current dividend yield of Novavax is .
When does Novavax pay dividends?
Novavax pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Novavax?
Novavax paid dividends every year for the past 0 years.
What is the dividend of Novavax?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Novavax located?
Novavax is assigned to the 'Health' sector.
Wann musste ich die Aktien von Novavax kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Novavax from 6/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/13/2024.
When did Novavax pay the last dividend?
The last dividend was paid out on 6/13/2024.
What was the dividend of Novavax in the year 2023?
In the year 2023, Novavax distributed 0 USD as dividends.
In which currency does Novavax pay out the dividend?
The dividends of Novavax are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Novavax stock can be added to a savings plan with the following providers: Trade Republic and Scalable Capital
Andere Kennzahlen von Novavax
Our stock analysis for Novavax Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novavax Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
